| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Guselkumab |
| Brand | Tremfya® |
| Indication | For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2017 |
| Rapid review completed | 06/02/2018 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations: April 2018